Summit Therapeutics plc : Miscellaneous
Summit Therapeutics plc
("Summit" or the "Company")
SUMMIT APPOINTS PANMURE GORDON AS JOINT BROKER
Oxford, UK, 16 November 2017- Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces the appointment of Panmure Gordon as joint broker with immediate effect to act alongside N+1 Singer.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy and the infectious disease C. difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
Contacts
| Summit Glyn Edwards / Richard Pye (UK office) Erik Ostrowski / Michelle Avery (US office)
|
Tel: +44 (0)1235 443 951 |
| Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Tony Rawlinson
|
Tel: +44 (0)20 7213 0880 |
| N+1 Singer (Joint Broker) Aubrey Powell / Jen Boorer
|
Tel: +44 (0)20 7496 3000 |
| Pamure Gordon (Joint Broker) Freddy Crossley / Duncan Monteith, Corporate Finance Tom Salvesen, Corporate Broking |
Tel: +44 (0)20 7886 2500 |
| MacDougall Biomedical Communications (US) Karen Sharma |
Tel: +1 781 235 3060 ksharma@macbiocom.com
|
| Consilium Strategic Communications (UK) Mary-Jane Elliott / Sue Stuart / Jessica Hodgson / Philippa Gardner |
Tel: +44 (0)20 3709 5700 summit@consilium-comms.com |
-END-